Ya‐Zhen Qin

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

Hong‐Hu Zhu, Xiaohui Zhang, Ya‐Zhen Qin et al. · Blood · 2013 · 324 citations · Full text

Medicine, Oncology, Outcomes Research +7

Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

Chen‐Hua Yan, Dai‐Hong Liu, Kai‐Yan Liu et al. · Blood · 2012 · 291 citations · Full text

Medicine, Hematology, Immunology +17

In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification

Yu Wang, Depei Wu, Qifa Liu et al. · Blood · 2014 · 130 citations

Medicine, Molecular Medicine, Oncology +11

Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia

Huan Chen, Kai‐Yan Liu, Lan‐Ping Xu et al. · Journal of Hematology & Oncology · 2012 · 103 citations · Full text

Medicine, Hematology, Oncology +17

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Qian Jiang, Zongru Li, Ya‐Zhen Qin et al. · Journal of Hematology & Oncology · 2022 · 99 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11